Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUAK1 | O60285 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | ABL2 | P42684 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 3/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513018 | 0.83 | XDH (0.39) | ABL1XDHKDM4EALDH1A1ELANE | |
| SCHEMBL586003 | 0.81 | XDH (0.39) | SRCABL1EGFRABL2XDH | |
| SCHEMBL586526 | 0.81 | XDH (0.39) | ABL1XDHELANE | |
| SCHEMBL586793 | 0.74 | PDE10A (0.39) | SRCXDHMTNR1ACTSL | |
| SCHEMBL579200 | 0.74 | XDH (0.41) | XDHKDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL8513959 | 0.73 | ELANE (0.55) | XDHELANE | |
| SCHEMBL18590930 | 0.73 | MTNR1A (0.41) | SRCABL1EGFRABL2MTNR1A | |
| SCHEMBL8511874 | 0.73 | XDH (0.37) | ABL1XDHELANE | |
| SCHEMBL586908 | 0.71 | PTPN11 (0.33) | SRCMTNR1AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9880034 | 0.71 | NUAK1 (0.37) | NUAK1MTNR1AKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2417133-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117935-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117935-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | NUAK1 3547/4885SRC 3244/4885ABL1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.